DRMA(DRMA)
DRMA
Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.
Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.
| Metric | FY2026E | FY2027E |
|---|---|---|
| Revenue Avg | $100,000 | $750,000 |
| Low | $100,000 | $750,000 |
| High | $100,000 | $750,000 |
| EBITDA Avg | — | — |
| Low | — | — |
| High | — | — |
| EBIT Avg | — | — |
| Low | — | — |
| High | — | — |
| Net Income Avg | $-2M | $-1M |
| Low | $-2M | $-1M |
| High | $-2M | $-1M |
| EPS Avg | $-2.21 | $-1.52 |
| Low | $-2.21 | $-1.52 |
| High | $-2.21 | $-1.52 |
| Analysts (Rev / EPS) | 1 / 1 | 1 / 1 |
| Metric | Q3 2026 | Q4 2026 |
|---|---|---|
| Revenue Avg | $25,000 | $75,000 |
| Low | $25,000 | $75,000 |
| High | $25,000 | $75,000 |
| EBITDA Avg | — | — |
| Low | — | — |
| High | — | — |
| EBIT Avg | — | — |
| Low | — | — |
| High | — | — |
| Net Income Avg | $-2M | $-2M |
| Low | $-2M | $-2M |
| High | $-2M | $-2M |
| EPS Avg | $-0.63 | $-0.56 |
| Low | $-0.63 | $-0.56 |
| High | $-0.63 | $-0.56 |
| Analysts (Rev / EPS) | 1 / 1 | 1 / 1 |